Biotechnology Industry on the Upswing -- Aeterna Zentaris and Elite Pharmaceuticals to Benefit
January 25 2012 - 8:20AM
Marketwired
The biotechnology industry has performed well in the early stages
of 2012. The iShares NASDAQ Biotechnology Index is presently up
nearly eight percent month-on-month as the industry continues to
recover nicely from the global economic crisis. According to a
recent report from Global Industry Analysts, Inc. (GIA) the
improving economic conditions have led to an increase in funding
for the biotechnology industry. The Paragon Report examines
investing opportunities in the Biotechnology Industry and provides
equity research on Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
and Elite Pharmaceuticals Inc. (OTCBB: ELTP). Access to the full
company reports can be found at:
www.paragonreport.com/AEZS www.paragonreport.com/ELTP
GIA predicts the Global Biotechnology Market to Surpass US$320
Billion by 2015, as increased availability of funding for R&D,
expanding use of biotechnology in agriculture and medical sciences,
and favorable government initiatives are expected to drive growth
in the biotechnology industry.
GIA argues that developing markets, especially India and China,
will emerge as major agricultural and industrial biotechnology
markets owing to rapid increase in population and income levels.
"The two countries are emerging as key markets for biotech drugs
due to their rich talent pool and low cost of investment," GIA
stated in a press release.
The Paragon Report provides investors with an excellent first
step in their due diligence by providing daily trading ideas, and
consolidating the public information available on them. For more
investment research on the biotechnology industry register with us
free at www.paragonreport.com and get exclusive access to our
numerous stock reports and industry newsletters.
Elite Pharmaceuticals, Inc. develops oral sustained and
controlled release products. Elite's strategy includes assisting
partner companies in the life cycle management of products, to
improve off-patent drug products, and developing generic versions
of controlled release drug products with high barriers to entry.
Last week the company announced that the initial shipment of
methadone hydrochloride 10 mg tablets has been made to
ThePharmaNetwork, LLC, and its wholly owned subsidiary, Ascend
Laboratories, LLC (together "TPN") under the commercial
Manufacturing and Supply Agreement.
Aeterna Zentaris is a late-stage oncology drug development
company currently investigating potential treatments for various
cancers including colorectal, multiple myeloma, endometrial,
ovarian, prostate and bladder cancer.
The Paragon Report has not been compensated by any of the
above-mentioned publicly traded companies. Paragon Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.paragonreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024